Current Oncology Clinical Research

For more information, call Clinical Research Associate Penny Ekegren R.N., B.S.N., at 419-526-8018.

Primary Site

Breast Cancer

Type	Protocol	Eligibility	Treatment
Adjuvant	SWOG S1007	1-3 Positive Nodes ER Positive HER2 Negative OncoType Recurr. Score = 25 or less (OncoType done by Protocol)	Encodrine therapy+/- Chemo (chemo regimens in protocol per standard of care)
NeoAdjuvant	CALGB 40603	Triple Negative Invasice Breast Cancer	Neo-Adjuvant: Chemo given PRIOR TO LUMPECTOMY
Adjuvant	NSABP B-43	HER2 Positive DCIS Respected by Lumpectomy (HER2 testing done at central lab) NO invasive components	Radiation Therapy +/- concurrent Herceptin
Adjuvant	SWOG S0221	Node Positive OR Node Neg. > 2 cm OR ER/PR Neg > 1 cm	AC + Neulasta x 4 cycles: followed by 2 arms: 1) q 2 wk Taxol + Neulasta x 6 2) wkly Taxol x 12 Hormonal Rx for ER +; Herceptin for HER2+
Adjuvant	NSABP B-39/ RTOG 0413	DCIS<50 years of age or Invasive>18 yrs Status Post Lumpectomy: Stage 0, 1, or II; Tumor size<3.0 cm; No more than 3 Positive Nodes Accrual CLOSED for >50 years with Node Neg/ER+	Whole Breast Irradiation versus Partial Breast Irradiation

Colorectal Cancer

Type

Protocol

Eligibility

Treatment

Adjuvant
Stage III

CALGB
C80702

Colon Stage III

6 versus 12 treatments of adjuvant FOLFOX plus:
Celecoxib (Celebrex) or Placebo

Metastatic
(Untreated)

CALGB
C80405

Wild Type KRAS
Locally Advanced or Metastatic
No prior treatment for Metastatic
disease

Arm A = Avastin followed by
FOLFOX or FOLFIRI
Arm B = Cetuximab followed by
FOLFOX or FOLFIRI

Lung Cancer

Type	Protocol	Eligibility	Treatment
NSCLC Stage IB- IIIA	E1505	Completely Resected No Prior treatment	Adjuvant Chemotherapy (see fact sheet) +/- Bevacizumab (Avastin)
NSCLC Stage IIIA N2+	RTOG 0839 Phase II	Stage IIIA (T1-T3) Single primary lung parenchymal lesion and N2 Positive ipsilateral mediastinal nodes	Induction Pre-Operative Chemoradiation with Carboplatin & Paclitaxel +/- Panitumumab concurrent with 6 wks radiation. Reassess: resect if no progression. Then consolidation chemo of Paclitaxel and Carboplatin q 21 days x 2.

Prostate Cancer

Type	Protocol	Eligibility	Treatment
No Prior Rx.	RTOG 0815	Clinically localized Adencarcinoma Lymph node negative Dx'd in last 6 mo as Intermediate risk for recurrence: with one or more of the following: Gleason Score 7 PSA>10 but </= 20 ClinicalStage T2b-T2c	Dose-escalated radiotherapy +/- Short Term Androgen Deprivation Therapy
No Prior Rx. Hormone Rx. OK	RTOG 0232	Clinical Stage: T1c-T2b Combined Gleason=7 if PSA <10 Combined Gleason=<7 if PSA 10-20	Combined External Beam Rad. Rx + Transperineal Interstitial Permanent Brachytherapy Vs Brachytherapy Alone
Companion Study to R032	RTOG 0612	Patients enrolled in RTOG 0232	Investigating Markers of Radiation Outcome using DNA Microarry Analysis